The reduction of DNA damage repair capacity in terminally differentiated cells may be involved in sensitivity to cancer chemotherapy drugs; however, the underlying molecular mechanism is still not fully understood. Herein, we evaluated the role of miR-638 in the regulation of DNA damage repair in terminally differentiated cells. Our results show that miR-638 expression was up-regulated during cellular terminal differentiation and involved in mediating DNA damage repair processes. Results from a luciferase reporting experiment show that structural maintenance of chromosomes (SMC)1A was a potential target of miR-638; this was verified by western blot assays during cell differentiation and DNA damage induction. Overexpression of miR-638 enhanced the sensitivity of cancer cells to cisplatin, thus reducing cell viability in response to chemotherapy drug treatment. Furthermore, miR-638 overexpression affected DNA damage repair processes by interfering with the recruitment of the DNA damage repair-related protein, γH2AX, to DNA break sites. These findings indicate that miR-638 might act as a sensitizer in cancer chemotherapy and accompany chemotherapy drugs to enhance chemotherapeutic efficacy and to improve the chance of recovery from cancer.
The transcription factor Sex-determining region Y-box protein 3 (SOX3) is well known for its critical roles in sex determination and cell differentiation; however, its function in antiviral innate immunity remains unexplored. This study uncovered how SOX3, induced by viral infections, modulates type I interferon (IFN-I) responses. RNA sequencing, quantitative PCR, and immunoblot analysis collectively revealed that SOX3 overexpression suppresses virus-induced interferon beta 1(IFN-β) promoter activation and significantly inhibits the expression of key antiviral interferon-stimulated genes (ISGs), including ISG15 and interferon induced protein with tetratricopeptide repeats 1 (IFIT1). Conversely, the knockdown of SOX3 enhanced IFN-β production and ISGs expression, confirming its role as a negative regulator of antiviral immunity. Mechanistically, chromatin immunoprecipitation sequencing (ChIP-seq) identified SOX3 binding specifically at the AKT serine/threonine kinase 1(AKT1) locus. Further analysis demonstrated that SOX3 directly upregulates AKT1 expression, subsequently increasing phosphorylation and inactivation of the tumor suppressor phosphatase and tensin homolog (PTEN). Inactivation of PTEN inhibited interferon regulatory factor 3 (IRF3) nuclear translocation, leading to reduced IFN-β expression. Thus, our findings uncover a previously uncharacterized SOX3-AKT1-PTEN signaling axis in the regulation of antiviral innate immunity, providing new insights into immune evasion strategies and highlighting potential therapeutic targets to enhance antiviral responses.